July 30, 2021 - ROSEN LOGO.jpg
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE
06 mars 2023 17h16 HE | The Rosen Law Firm PA
NEW YORK, March 06, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2,...
Close Up Logo HD Blue.jpg
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
06 mars 2023 11h50 HE | The Law Offices of Frank R. Cruz
LOS ANGELES, March 06, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
Fate Therapeutics.jpg
Fate Therapeutics to Present at Upcoming March Investor Conferences
03 mars 2023 16h01 HE | Fate Therapeutics, Inc.
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
01 mars 2023 21h00 HE | Bragar Eagel & Squire
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE
01 mars 2023 11h34 HE | The Rosen Law Firm PA
NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2,...
Fate Therapeutics.jpg
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
28 févr. 2023 16h01 HE | Fate Therapeutics, Inc.
Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents, and Receivables Multi-dose Treatment Cohorts Initiated in FT576 Phase 1 Study for Multiple Myeloma; Interim Clinical Data from...
Close Up Logo HD Blue.jpg
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
28 févr. 2023 12h15 HE | The Law Offices of Frank R. Cruz
LOS ANGELES, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
24 févr. 2023 21h00 HE | Bragar Eagel & Squire
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FATE
24 févr. 2023 16h44 HE | The Rosen Law Firm PA
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2,...
Close Up Logo HD Blue.jpg
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
22 févr. 2023 11h49 HE | The Law Offices of Frank R. Cruz
LOS ANGELES, Feb. 22, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...